These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28315862)

  • 1. The Evolving Role of Rituximab in Adult Minimal Change Glomerulopathy.
    Brown LC; Jobson MA; Payan Schober F; Chang EH; Falk RJ; Nachman PH; Pendergraft WF
    Am J Nephrol; 2017; 45(4):365-372. PubMed ID: 28315862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study.
    Katsuno T; Masuda T; Saito S; Kato N; Ishimoto T; Kato S; Kosugi T; Tsuboi N; Kitamura H; Tsuzuki T; Ito Y; Maruyama S
    Clin Exp Nephrol; 2019 Feb; 23(2):207-214. PubMed ID: 30121802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance.
    Guitard J; Hebral AL; Fakhouri F; Joly D; Daugas E; Rivalan J; Guigonis V; Ducret F; Presne C; Pirson Y; Hourmant M; Glachant JC; Vendrely B; Moranne O; Faguer S; Chauveau D
    Nephrol Dial Transplant; 2014 Nov; 29(11):2084-91. PubMed ID: 24920841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab for minimal change disease in adults: long-term follow-up.
    Bruchfeld A; Benedek S; Hilderman M; Medin C; Snaedal-Jonsdottir S; Korkeila M
    Nephrol Dial Transplant; 2014 Apr; 29(4):851-6. PubMed ID: 24121763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A series of patients with minimal change nephropathy treated with rituximab during adolescence and adulthood.
    Dekkers MJ; Groothoff JW; Zietse R; Betjes MG
    BMC Res Notes; 2015 Jun; 8():266. PubMed ID: 26112053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.
    Munyentwali H; Bouachi K; Audard V; Remy P; Lang P; Mojaat R; Deschênes G; Ronco PM; Plaisier EM; Dahan KY
    Kidney Int; 2013 Mar; 83(3):511-6. PubMed ID: 23325085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is splenectomy necessary for immune thrombocytopenic purpura? The role of rituximab in patients with corticosteroid resistance in a single-center experience.
    Zhang C; Liu HF; Chen XH; Gao L; Gao L; Liu Y; Kong PY; Sun AH; Zhang X
    Clin Ther; 2014 Mar; 36(3):385-8. PubMed ID: 24594069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab in treatment of idiopathic glomerulopathy.
    El-Reshaid K; Sallam HT; Hakim AA; Al-Attiyah R
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):973-8. PubMed ID: 22982909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Clinical Course of Minimal Change Nephrotic Syndrome With Onset in Adulthood or Late Adolescence: A Case Series.
    Maas RJ; Deegens JK; Beukhof JR; Reichert LJ; Ten Dam MA; Beutler JJ; van den Wall Bake AWL; Rensma PL; Konings CJ; Geerse DA; Feith GW; Van Kuijk WH; Wetzels JF
    Am J Kidney Dis; 2017 May; 69(5):637-646. PubMed ID: 28089478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study).
    Rémy P; Audard V; Natella PA; Pelle G; Dussol B; Leray-Moragues H; Vigneau C; Bouachi K; Dantal J; Vrigneaud L; Karras A; Pourcine F; Gatault P; Grimbert P; Ait Sahlia N; Moktefi A; Daugas E; Rigothier C; Bastuji-Garin S; Sahali D;
    Kidney Int; 2018 Dec; 94(6):1217-1226. PubMed ID: 30385039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy.
    Yang T; Nast CC; Vo A; Jordan SC
    Nephrol Dial Transplant; 2008 Jan; 23(1):377-80. PubMed ID: 17981884
    [No Abstract]   [Full Text] [Related]  

  • 12. Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label, nonrandomized cohort trial.
    Li H; Shi X; Shen H; Li X; Wang H; Li H; Xu G; Chen J
    Clin Ther; 2012 May; 34(5):1112-20. PubMed ID: 22503105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic features and treatment response in nephrotic IgA nephropathy with minimal change disease.
    Qin J; Yang Q; Tang X; Chen W; Li Z; Mao H; Jiang Z; Huang F; Yu X
    Clin Nephrol; 2013 Jan; 79(1):37-44. PubMed ID: 22948116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age of Onset and Disease Course in Biopsy-Proven Minimal Change Disease: An Analysis From the Cure Glomerulonephropathy Network.
    Chen DP; Helmuth ME; Smith AR; Canetta PA; Ayoub I; Mucha K; Kallash M; Kopp JB; Gbadegesin R; Gillespie BW; Greenbaum LA; Parekh RS; Hunley TE; Sperati CJ; Selewski DT; Kidd J; Chishti A; Reidy K; Mottl AK; Gipson DS; Srivastava T; Twombley KE;
    Am J Kidney Dis; 2023 Jun; 81(6):695-706.e1. PubMed ID: 36608921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of repeat-dose rituximab maintenance therapy for minimal change disease in adults.
    Taguchi S; Ohtake T; Mochida Y; Ishioka K; Moriya H; Hidaka S; Kobayashi S
    Clin Exp Nephrol; 2020 Dec; 24(12):1132-1139. PubMed ID: 32761467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab as a Therapeutic Option for Steroid-Sensitive Minimal Change Nephrotic Syndrome in Adults.
    Iwabuchi Y; Moriyama T; Itabashi M; Takei T; Nitta K
    Contrib Nephrol; 2018; 195():12-19. PubMed ID: 29734146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease.
    Liu D; Zhou Z; Wang M; Nie S; Li J; Hu B; He W; Wang G; Ai J
    BMC Nephrol; 2021 Jul; 22(1):242. PubMed ID: 34210283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective single-arm cohort study of steroid-dependent minimal change nephrotic syndrome treated with very low-dose rituximab.
    Fujimoto K; Kagaya Y; Kumano S; Fujii A; Tsuruyama Y; Matsuura T; Yamazaki K; Nomura K; Okada K; Okino K; Adachi H; Furuichi K; Yokoyama H
    Clin Nephrol; 2021 Jan; 95(1):29-36. PubMed ID: 33074094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease.
    Papakrivopoulou E; Shendi AM; Salama AD; Khosravi M; Connolly JO; Trompeter R
    Nephrology (Carlton); 2016 Oct; 21(10):893-900. PubMed ID: 26860320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of remission following a single dose of rituximab alone in a patient with minimal change nephrotic syndrome.
    Amemiya N; Takei T; Kojima C; Nokiba H; Itabashi M; Nitta K
    Clin Exp Nephrol; 2011 Dec; 15(6):933-6. PubMed ID: 21823044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.